Clinical Trial Results:
            EDEMA3: Evaluation of DX-88’s Effects in Mitigating Angioedema 
A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant plasma kallikrein inhibitor) for the treatment of acute attacks of Hereditary Angioedema
    
|     Summary | |
|     EudraCT number | 2005-003819-71 | 
|     Trial protocol | BE GB IT | 
|     Global completion date | 
                                    01 Feb 2007
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    15 May 2021
                             | 
|     First version publication date | 
                                    15 May 2021
                             | 
|     Other versions | |
|     Summary report(s) | DX-88-14_Study Results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
